Triglycerides as a Shared Risk Factor between Dementia and Atherosclerotic Cardiovascular Disease: A Study of 125 727 Individuals.
暂无分享,去创建一个
B. Nordestgaard | R. Frikke-Schmidt | A. Tybjærg‐Hansen | M. Christoffersen | S. Afzal | L. T. Nordestgaard | L. Nordestgaard
[1] B. Nordestgaard,et al. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention , 2020, European heart journal.
[2] Naaheed Mukadam,et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.
[3] R. Giugliano,et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. , 2019, Circulation.
[4] B. Nordestgaard,et al. High lipoprotein(a) and high risk of mortality. , 2019, European heart journal.
[5] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[6] B. Nordestgaard,et al. Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort , 2019, European heart journal.
[7] Deepak L. Bhatt,et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.
[8] D. Llewellyn,et al. Which Risk Factors Causally Influence Dementia? A Systematic Review of Mendelian Randomization Studies , 2018, Journal of Alzheimer's disease : JAD.
[9] B. Nordestgaard,et al. Chylomicronemia risk factors ranked by importance for the individual and community in 108 711 women and men , 2018, Journal of internal medicine.
[10] P. Barber,et al. Dementia risk and prevention by targeting modifiable vascular risk factors , 2018, Journal of neurochemistry.
[11] B. Nordestgaard,et al. Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study. , 2018, Clinical chemistry.
[12] Tanya M. Teslovich,et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.
[13] B. Winblad,et al. The worldwide costs of dementia 2015 and comparisons with 2010 , 2017, Alzheimer's & Dementia.
[14] K. Anstey,et al. Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis , 2016, Journal of Alzheimer's disease : JAD.
[15] Børge G Nordestgaard,et al. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. , 2016, JAMA internal medicine.
[16] R. Frikke-Schmidt,et al. Relation between plasma and brain lipids , 2016, Current opinion in lipidology.
[17] Dermot F. Reilly,et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease , 2018 .
[18] Alun D. Hughes,et al. Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase , 2016, Journal of the American College of Cardiology.
[19] Alexander E. Lopez,et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.
[20] B. Nordestgaard. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.
[21] B. Nordestgaard,et al. Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease , 2015, Alzheimer's & Dementia.
[22] Lars Bäckman,et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial , 2015, The Lancet.
[23] Anne Tybjærg-Hansen,et al. Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Blood Pressure as Mediators From Obesity to Ischemic Heart Disease , 2015, Circulation research.
[24] Alan D. Lopez,et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.
[25] Anette Varbo,et al. Triglycerides and cardiovascular disease , 2014, The Lancet.
[26] Kristine Yaffe,et al. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data , 2014, The Lancet Neurology.
[27] B. Nordestgaard,et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.
[28] Tanya M. Teslovich,et al. Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.
[29] B. Nordestgaard,et al. Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.
[30] B. Nordestgaard,et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.
[31] B. Nordestgaard,et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.
[32] B. Nordestgaard,et al. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population , 2011, Annals of neurology.
[33] Statins for the treatment of dementia , 2010, Alzheimer's & Dementia.
[34] J. Danesh,et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.
[35] J. C. de la Torre. Vascular risk factor detection and control may prevent Alzheimer's disease. , 2010, Ageing research reviews.
[36] P. Amarenco,et al. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention , 2009, The Lancet Neurology.
[37] A. James,et al. The incorporation and metabolism of amyloid-beta into chylomicron-like lipid emulsions. , 2003, Journal of Alzheimer's disease : JAD.
[38] J. C. Torre,et al. Vascular Basis of Alzheimer's Pathogenesis , 2002 .
[39] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[40] R. Collins,et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.
[41] M W Knuiman,et al. Adjustment for regression dilution in epidemiological regression analyses. , 1998, Annals of epidemiology.
[42] R. Wootton,et al. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[43] R. Wootton,et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.